QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Krueger, C. D Articles by Pickard, A S. Search for Related Content PubMed PubMed Citation Articles by Krueger, C. D Articles by Pickard, A S.

ADVERSE DRUG REACTIONS

Bisphosphonate-Induced Osteonecrosis of the Jaw

Clinical Pharmacist, Drug Information; Clinical Assistant Professor, Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago

Patricia M West, PharmD BCPS

Associate Head of Clinical Transplant Research; Assistant Professor of Medicine; Clinical Assistant Professor of Pharmacy, College of Medicine, University of Illinois at Chicago

Matthew Sargent

Student, Honors College, University of Illinois at Chicago

Amy E Lodolce, PharmD BCPS

Assistant Director, Drug Information; Clinical Assistant Professor, Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago

A Simon Pickard, PhD

Assistant Professor, Department of Pharmacy Practice; Assistant Director, Center for Pharmacoeconomics Research, University of Illinois at Chicago

Reprints: Dr. Krueger, College of Pharmacy, 833 S. Wood St., Room 164, Mail Code 886, University of Illinois at Chicago, Chicago, IL 60612, fax 312/996-0448, ceckhoff{at}uic.edu

OBJECTIVE: To review the risk of osteonecrosis of the jaw associated with bisphosphonates.

DATA SOURCES: A MEDLINE search (1966-January 2007) and a search of International Pharmaceutical Abstracts (1970-January 2007) were conducted to identify relevant literature. Additional references were reviewed from selected articles.

STUDY SELECTION AND DATA EXTRACTION: Articles related to bisphosphonate-induced osteonecrosis of the jaw were reviewed and summarized. Inclusion criteria required that articles be either case studies or case series that were reporting actual cases linking osteonecrosis of the jaw with bisphosphonate use. Articles that addressed sites of osteonecrosis not involving the jaw, teaching cases (fictitious patients), and a retrospective claims analysis paper were excluded from consideration.

DATA SYNTHESIS: Bisphosphonates have recently been linked to osteonecrosis of the jaw, with the greatest incidence seen with the intravenous preparations zoledronic acid and pamidronate. Osteonecrosis refers to death of a part of the bone, resulting in decreased bone density. Although the majority of occurrences have been associated with the intravenous bisphosphonates, oral bisphosphonates have also been implicated. Other risk factors noted from reported cases include dental extraction or trauma to the jaw exposing part of the bone. It is difficult to determine an exact incidence of osteonecrosis of the jaw in the general population of patients prescribed bisphosphonates; however, the incidence in cancer patients is approximately 6-7%.

CONCLUSIONS: Although discontinuation of intravenous bisphosphonates in cancer patients has been recommended, stopping oral bisphosphonates prior to dental work cannot be universally endorsed at this time, since it is unknown whether this is effective in reducing the risk of osteonecrosis of the jaw. Treatment of this condition is not well established; therefore, efforts should be directed toward prevention. Pharmacists may further counsel patients to practice good oral hygiene and regularly follow up with their dentist during therapy. Current evidence suggests limited surgical debridement with systemic and local antibiotics as treatments.

Key Words: bisphosphonates, osteoporosis

Published Online, February 13, 2007. www.theannals.com, DOI 10.1345/aph.1H521